Fennec Pharmaceuticals (FENC) Retained Earnings (2010 - 2025)

Fennec Pharmaceuticals (FENC) has 16 years of Retained Earnings data on file, last reported at $1.2 million in Q4 2025.

• For the quarter ending Q4 2025, Retained Earnings rose 100.57% year-over-year to $1.2 million; the trailing twelve-month figure through Dec 2025 stood at $1.2 million (up 100.57% YoY), and the FY2025 full-year result was $1.2 million, up 100.57% from the prior year.
• Retained Earnings for Q4 2025 stood at $1.2 million, up from -$224.6 million in the prior quarter.
• Across five years, Retained Earnings topped out at $215.6 million in Q3 2023 and bottomed at -$224.6 million in Q3 2025.
• The 5-year median for Retained Earnings is -$179.1 million (2021), against an average of -$110.2 million.
• The widest annual swing landed in 2023, when Retained Earnings surged 209.81%; it then sank 17773.45% in 2024.
• A 5-year view of Retained Earnings shows it stood at $1.2 million in 2021, then changed by 0.0% to $1.2 million in 2022, then changed by 0.0% to $1.2 million in 2023, then tumbled by 17773.45% to -$219.7 million in 2024, then soared by 100.57% to $1.2 million in 2025.
• The last three Retained Earnings figures came in at $1.2 million (Q4 2025), -$224.6 million (Q3 2025), and -$224.0 million (Q2 2025), per Business Quant data.

Peer Comparison